Compare Mondaycom Ltd (MNDY) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Smith & Nephew plc — how do they compare? Mondaycom Ltd trades at $88.48 (market cap $3.76B), while Smith & Nephew plc trades at $27.21 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 3× Mondaycom Ltd's market cap, and Smith & Nephew plc pays a 2.95% dividend while Mondaycom Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Smith & Nephew plc for 121 Days on average.
| MNDY | SNN | |
|---|---|---|
Market Cap | $3.76B | $11.10B |
Volume | 836,200 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $205.24 | $37.17 |
52-Week Low | $58.81 | $26.42 |
Typical Hold Time | 16 Days | 121 Days |
Enterprise Value | $2.92B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $88.41, up 5.87% in the last session, showing strong momentum near 52-week highs. The stock maintains a bullish technical outlook with consistent earnings beats and robust revenue growth. Recent Q2 2026 EPS of $1.48 exceeded expectations by 33%, while enterprise customer growth accelerated to 37% year-over-year. The company's Elevate '26 conference highlights AI integration efforts, positioning it for continued market share gains in the work management software sector.
With 65% analyst buy ratings and a $108.64 consensus price target, MNDY offers 23% upside potential. However, elevated valuation multiples (P/E 37.7, EV/EBITDA 53.5) and increasing competition from Meta's enterprise push present near-term risks. The stock's current RSI near 88 suggests overbought conditions, though fundamental growth drivers remain intact for long-term investors.
SNN trades at $27.10, near its 52-week low, with a bearish technical signal. The company reported solid fundamentals with revenue growth to $6.16B in 2025 and a net income margin of 10.08%. Recent product launches, like the EVOS PELVIC System, aim to strengthen its medical technology portfolio. Cash flow from operations remains strong at $1.29B, though net cash flow was negative $64M in 2025.
The outlook is mixed: strong profitability and innovation support long-term value, but near-term headwinds include analyst downgrades and competitive pressures. Risks involve execution challenges and market sentiment. The stock presents a cautious opportunity for value investors, balancing solid fundamentals against current bearish trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
